Polymyalgia rheumatica in the 2018–2020 clinical guidelines. Part I. At-risk groups, adjuvant therapy

Main Article Content

О.G. Puzanovа

Abstract

At the beginning of the Healthy Ageing Decade, a number of guidelines were published describing management of the rheumatic diseases of the elderly. The aim of the paper is to cha­racterize and discuss the Italian Society of Rheumatology’s guideline for polymyalgia rheumatica (2020) and the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the American Society of Nuclear Cardio­logy’s (2018) recommendation for positron-emission tomography/computed tomography imaging to diagnose the large vessel vasculitis and polymyalgia rheumatica. The following methods were used: original texts of recommedations, their content and methodology behind the development of both guidelines were studied by means of information analysis and compared with the recommendations for the management of polymyalgia rheumatica and giant cell arteritis elaborated in 2018–2020 by the European League Against Rheumatism, American College of Rheumatology; the German, Austrian, Swiss and British rheumatological societies; the European Headache Federation and their references. We’ve established the priority of consensus approach for the development of modern guidelines for polymyalgia rheumatica. The specific feature of the Italian guideline’s development is the search for prototypes restric­ted to the two evidence-based medicine databases and the grey li­terature as well as selection of three international guidelines for ­adaptation, one of them elaborated by the societies for nuclear me­dicine. The following issues were updated: the patient management in primary care (whose algorithm is proposed), including the conserted clinical decision-making and alertness to the giant cell arteritis. Out of the first-line therapy tools, only the initial doses of glucocorticoids are evidence-based, and their reduction is allowed as an alternating regimen. The ineffectiveness of hydroxichloroquine use is justified, while both azathioprine and alternative medical drugs are not subject to discussion. It is necessary to identify the risk factors for vasculitis and its relapses, longterm glucocorticoid use and their side effects. For the first time, the use of positron-emission tomography/computed tomography is recommended for detecting of vasculitis. The recommendation for adjuvant therapy with methotrexate and abstaining from the biologic agents is found the most evidence-based, strongest and consistent; referral to a rheumatologist being the least agreed-on position. Conclusion. Solving such an urgent healthcare problem as improving the quality of polymyalgia rheumatic management suggests the medical standards being raised on the most clinically important issues, the importance of at-risk patient identification and referral to rheumatologists and ophthalmologists, and consideration of the methotrexate’s benefits.

Article Details

How to Cite
Puzanovа О. “Polymyalgia Rheumatica in the 2018–2020 Clinical Guidelines. Part I. At-Risk Groups, Adjuvant Therapy”. PAIN, JOINTS, SPINE, vol. 10, no. 4, Nov. 2020, pp. 161-73, doi:10.22141/2224-1507.10.4.2020.220456.
Section
Reviews

References

World Health Organization. Development of a proposal for a Decade of Healthy Ageing 2020-2030. 2019 Dec; Provisional agenda item 17: EB146/23. Available from: https://apps.who.int/gb/ebwha/pdf_files/EB146/B146_23-en.pdf.

Lahaye C, Tatar Z, Dubost JJ, Tournadre A, Soubrier M. Management of inflammatory rheumatic conditions in the elderly. Rheumatology (Oxford). 2019 May 1;58(5):748-764. https://doi.org/10.1016/j.clineuro.2016.04.019.

Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul Sultan A. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis. 2018 Dec;77(12):1750-1756. https://doi.org/10.1136/annrheumdis-2018-213883.

Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011 Nov;50(11):1982-90. https://doi.org/10.1093/rheumatology/ker017.

Shbeeb I, Challah D, Raheel S, Crowson CS, Matteson EL. Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population. Arthritis Care Res (Hoboken). 2018 Apr;70(4):643-647. https://doi.org/10.1002/acr.23320.

Dubost JJ, Pereira B, Fan A, Soubrier M. What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica? Ann Rheum Dis. 2019 Aug 27:annrheumdis-2019-216050. https://doi.org/10.1136/annrheumdis-2019-216050.

Albrecht K, Callhoff J, Zink A. Long-term trends in rheumatology care : Achievements and deficits in 25 years of the German national rheumatology database. Z Rheumatol. 2019 Dec;78(Suppl 2):65-72. https://doi.org/10.1007/s00393-019-0680-1.

Satybaldyev AM. The evolution of diagnosis of polymyalgia rheumatica. 2019;57(6):693-698. https://doi.org/10.14412/1995-4484-2019-693-698.

Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N. "I suddenly felt I'd aged": a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns. 2015 May;98(5):645-50. https://doi.org/10.1016/j.pec.2014.12.013.

González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017 Oct 7;390(10103):1700-1712. https://doi.org/10.1016/s0140-6736(17)31825-1.

Sobrero A, Manzo C, Stimamiglio A. The role of the general practitioner and the out-of-hospital public rheumatologist in the diagnosis and follow-up of patients with polymyalgia rheumatica. Reumatismo. 2018 Mar 27;70(1):44-50. https://doi.org/10.4081/reumatismo.2018.1036.

Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract. 2013 May;63(610):e361-6. https://doi.org/10.3399/bjgp13x667231.

Manger B. Checkliste XXL Rheumatologie. Stuttgart, New York: Georg Thieme Verlag; 2005. 576 p.

Faez S, Lobo AM, Unizony SH, Stone JH, Papaliodis GN, Sobrin L. Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature. Clin Rheumatol. 2016 Jan;35(1):251-8. https://doi.org/10.1007/s10067-014-2558-6.

Arai T, Tanaka R, Kaburaki T. Ocular Inflammation Associated with Polymyalgia Rheumatica without Concomitant Giant-Cell Arteritis: A Report of Three Cases. Ocul Immunol Inflamm. 2018;26(5):779-782. https://doi.org/10.1080/09273948.2017.1278776.

Hancock AT, Mallen CD, Muller S, et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014 Sep 16;186(13):E495-501. https://doi.org/10.1503/cmaj.140266.

Pujades-Rodriguez M, Duyx B, Thomas SL, Stogiannis D, Smeeth L, Hemingway H. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart. 2016 Mar;102(5):383-9. https://doi.org/10.1136/heartjnl-2015-308514.

Bassendine MF, Bridge SH. Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. Eur J Rheumatol. 2019 Dec 16;7(1):37-40. https://doi.org/10.5152/eurjrheum.2019.19152.

Hayward RA, Rathod T, Muller S, Hider SL, Roddy E, Mallen CD. Association of polymyalgia rheumatica with socioeconomic status in primary care: a cross-sectional observational study. Arthritis Care Res (Hoboken). 2014 Jun;66(6):956-60. https://doi.org/10.1002/acr.22276.

Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991 Mar;34(3):351-6. https://doi.org/10.1002/art.1780340313.

Salaffi F, De Angelis R, Grassi W; MArche Pain Prevalence; INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):819-28.

De Socio A, Perrotta FM, Grasso GM, Lubrano E. Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study. Postgrad Med. 2018 Jan;130(1):137-141. https://doi.org/10.1080/00325481.2018.1399774.

Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484-92. https://doi.org/10.1136/annrheumdis-2011-200329.

Dejaco C, Singh YP, Perel P, et al; European League Against Rheumatism; American College of Rheumatology. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015 Oct;74(10):1799-807. https://doi.org/10.1136/annrheumdis-2015-207492.

Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis. 2014 Jun;73(6):1190-3. https://doi.org/10.1136/annrheumdis-2013-204167.

Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-643. https://doi.org/10.1136/annrheumdis-2017-212649.

Slart RHJA; Writing group; Reviewer group; Members of EANM Cardiovascular; Members of EANM Infection & Inflammation; Members of Committees, SNMMI Cardiovascular; Members of Council, PET Interest Group; Members of ASNC; EANM Committee Coordinator. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1250-1269. https://doi.org/10.1007/s00259-018-3973-8.

Buttgereit F, Brabant T, Dinges H, et al. S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol. 2018 Jun;77(5):429-441. https://doi.org/10.1007/s00393-018-0476-8. (in German).

Puzanova OG, Moshkovska YuO, Sobol VO. Polymyalgia rheumatica: concerted efforts of the European rheumatological societies. Bolʹ, sustavy, pozvonočnik. 2020;3:118-126. https://doi.org/10.22141/2224-1507.10.3.2020.212033.

Ughi N, Sebastiani GD, Gerli R, et al. The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica. Reumatismo. 2020 Apr 10;72(1):1-15. https://doi.org/10.4081/reumatismo.2020.1268.

Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol. 2012 Sep;8(9):509-21. https://doi.org/10.1038/nrrheum.2012.97.

Brouwers MC, Kho ME, Browman GP, et al; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010 Dec 14;182(18):E839-42. https://doi.org/10.1503/cmaj.090449.

Fervers B, Burgers JS, Voellinger R, et al; ADAPTE Collaboration. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf. 2011 Mar;20(3):228-36. https://doi.org/10.1136/bmjqs.2010.043257.

Oxford Centre for Evidence-based Medicine. Levels of Evidence. March 2009. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009.

Campbell AM, Martin JR, Erstad BL. Corticosteroid Tapering Regimens in Rheumatic Disease: A Systematic Review. J Clin Rheumatol. 2020 Mar;26(2):41-47. https://doi.org/10.1097/rhu.0000000000000917.

Lyzikov AN, Puzanova OH, Lyzikov AA. Giant cell arteritis: proven and debatable aspects of treatment. Bolʹ, sustavy, pozvonočnik. 2020;10(1):17-38. https://doi.org/10.22141/2224-1507.10.1.2020.199720.

Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018 Apr;38(4):569-577. https://doi.org/10.1007/s00296-017-3874-3.

Giollo A, Rossini M, Bettili F, et al. Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates. J Rheumatol. 2019 Mar;46(3):318-322. https://doi.org/10.3899/jrheum.180324.

Lee JH, Choi ST, Kim JS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013 Jun;33(6):1475-80. https://doi.org/10.1007/s00296-012-2580-4.

Hattori K, Hirano Y, Kojima T. Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone. Int J Rheum Dis. 2020 Nov;23(11):1581-1586. https://doi.org/10.1111/1756-185x.13978.

Quartuccio L, Gregoraci G, Isola M, De Vita S. Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients. Geriatr Gerontol Int. 2018 Sep;18(9):1410-1414. https://doi.org/10.1111/ggi.13460.

Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012 Mar;39(3):552-7. https://doi.org/10.3899/jrheum.110851.

Müller-Ladner U, Rau R. Methotrexat bei Autoimmunerkrankungen − Moderne Therapiekonzepte in der Rheumatologie, dermatologie und gastroenterologie. Bremen: UNI-MED; 2016. 118 p.

Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F; Brescia Rheumatology COVID-19 Study Group. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol. 2020 Sep;2(9):e549-e556. https://doi.org/10.1016/s2665-9913(20)30169-7.

Partington R, Helliwell T, Muller S, Abdul Sultan A, Mallen C. Comorbidities in polymyalgia rheumatica: a systematic review. Arthritis Res Ther. 2018 Nov 20;20(1):258. https://doi.org/10.1186/s13075-018-1757-y.

Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii32-ii42. https://doi.org/10.1093/rheumatology/kex424.

Netiazhenko VZ, Puzanova OG. Giant cell arteritis: epidemiology, diagnosis, prognosis. Bolʹ, sustavy, pozvonočnik. 2019;9(2):90-107. https://doi.org/10.22141/2224-1507.9.2.2019.172121. (in Russian).

Camellino D, Dejaco C, Buttgereit F, Matteson EL. Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis? Rheum Dis Clin North Am. 2019 Nov;45(4):549-567. https://doi.org/10.1016/j.rdc.2019.07.005.

Most read articles by the same author(s)